Cipla · Analyst questions, management answers, and the quality of the response where the ledger is available.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Questions audited
12
Answered directly
42%
Numeric claims
0
Consistency
—
Question ledger
Tushar Manudhane · Motilal Oswal Financial Services
directSo Lenalidomide is a significant impact sitting out there in the gross margin that you see. I think apart from that, in case of R&D, this quarter was a quarter where we purchased certain R&Ds and APIs as well for our R&D expenditure. That led to a significant explanation for the difference that you see out there.
Kunal Dhamesha · Macquarie
partialSo a significant portion of that comes from Lenalidomide, major portion of that. And there is a portion that comes on account of lanreotide as well. But important to note is that, as against what we had planned in lanreotide, it is lower than that we have achieved because of this shortage.
Kunal Dhamesha · Macquarie
evasiveSo that your assessment is not entirely correct in our lagging at the base because we can't share the numbers of Lenalidomide, unfortunately. It's so difficult for us to explain the entire gap.
Kunal Dhamesha · Macquarie
evasiveYeah. So we have mentioned four respiratory assets. One of them is generic Advair. There are two other fairly large material opportunities where we believe we have a full generic opportunity, which would stay like that for a certain period of time.
Neha Manpuria · Bank of America
directNo, none of them is coming from Pharmathen.
Neha Manpuria · Bank of America
partialYeah. So without necessarily giving the risk, if you set that your R&D expenses is about 7% of revenue, part of that 7% sits as material that you purchase, procure as well, which is both R&D and API, and we did that for certain molecules, including oligonucleotides. So what happens is that it is not a quarter regular consistent quarter phenomenon. In this quarter, we purchased, so therefore it can be lumpy as well. So you may not have it coming back in quarter four.
Neha Manpuria · Bank of America
declined2027 margin, we are not currently guiding towards for a reason that we've not completed our annual operating plan for the year, which needs to go to the board, and then we can give that guidance next quarter.
Damayanti Kerai · HSBC
evasiveYeah. So thank you for that question. The respiratory assets that we have are progressing well through their assessments, and we've been preparing for the launch as well in terms of operation-related activities that need to happen to prepare for the launch. So we are quite confident about those upcoming launches.
Surya Patra · PhillipCapital
evasiveSo Surya, let me just try and give you some color. So the Lenalidomide is a planned tapering phase which was known for quite some time. So that's happening as we speak. And in preparation for that, we've been working on the pipeline. And as we already mentioned, that pipeline is now looking closer.
Abdulkader Puranwala · ICICI Securities
directYeah. I think we'll have to revise the guidance. Yeah. The guidance will have to be revised because if we don't have lanreotide in one quarter, the numbers will be lower, right?
Chirag Dagli · DSP Asset Managers
directYeah. See, that's the guidance Chirag had given in the last quarter as well, where we said that our R&D expenses and estimate have gone up by about 50 basis points. Your 50 basis points would translate to somewhere around INR 150 crore. From that sense, yes, your number is very major.
Shrikant Akolkar · Nuvama
evasiveSo at the moment, we are focusing on tirzepatide. That's a fairly large opportunity with our European partnership with Lenalidomide. As you see from IQVIA data last month, the molecule was dropping upwards of INR 130 crore a month. So our efforts are primarily focused on that. On Sema, we will wait and watch as to how the market evolves.
